Sergio Santillana will become the next chief medical officer of Merrimack Pharmaceuticals (NASDAQ: [[ticker:MACK]]). Cambridge, MA-based Merrimack said that Santillana will start on June 12. Santillana most recently served as chief medical officer of Ariad Pharmaceuticals, a Cambridge company that was acquired by Japan-based Takeda Pharmaceutical earlier this year. His experience also includes posts at Takeda, GlaxoSmithKline (NYSE: [[ticker:GSK]]), and Eli Lilly (NYSE: [[ticker:LLY]]).
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
